MeiraGTx Revenue and Competitors

MeiraGTx, a London and New York-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. We are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). We are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. Our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.